Similarly, promising data were generated by administration of a C3 inhibitor, namely AMY-101, the administration of which in COVID-19 patients with severe ARDS safely reduced inflammation and ameliorated the syndrome [161, 162]; however, the proportion of patients with improved oxygenation did not reach statistical significance in larger trials [163]. Here, C3 is linked to COVID-19.